Pfizer

Pfizer's GLP-1 strategy has stumbled but is not dead. Lotiglipron was discontinued in 2023 due to elevated liver enzyme signals. Danuglipron, Pfizer's other oral small-molecule GLP-1 receptor agonist, was reformulated to a once-daily extended-release version in 2024 after twice-daily dosing showed unfavorable tolerability and dropout rates.

Pfizer remains a major potential entrant in the oral GLP-1 race against Lilly's orforglipron and Novo's oral semaglutide. The company also has substantial peptide-adjacent assets in oncology and rare disease, but for the metabolic-and-weight-loss editorial focus of this site, danuglipron is the relevant program. We update this profile when Pfizer makes a Phase 3 commitment or shelves the program.